Johnson & Johnson (JNJ) Stock Guide

July 02, 2020

Before we start: if you're looking for JNJ stock price, you can quickly find it out by visiting Finny and typing "JNJ quote". If you're looking for a quick scoop on JNJ stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "JNJ". You'll get all this info in one place. Or you can just type "JNJ news" to get the latest stock news.

Looking to buy or sell Johnson & Johnson (JNJ)? Interested in getting the full scoop on JNJ, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this JNJ stock guide, we'll address key questions about JNJ, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are JNJ earnings?
2. When is JNJ earnings date?
3. What is JNJ dividend?
4. What is JNJ dividend yield?
5. What is JNJ stock forecast (i.e., prediction)?
6. JNJ buy or sell? What is JNJ Finny Score?
7. What are the reasons to buy JNJ? Why should I buy JNJ stock?
8. What are the reasons to sell JNJ? Why should I sell JNJ stock?
9. What are JNJ key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are JNJ earnings?

JNJ trailing 12-month earnings per share (EPS) is $6.41.

2. When is JNJ earnings date?

JNJ earnings date is July 16, 2020.

3. What is JNJ dividend?

JNJ forward dividend is $4.04.

4. What is JNJ dividend yield?

JNJ forward dividend yield is 2.75%.

Analyst Predictions

5. What is JNJ stock forecast (i.e., prediction)?

Based on JNJ analyst price targets, JNJ stock forecast is $164.17 (for a year from now). That means the average analyst price target for JNJ stock is $164.17. The prediction is based on 23 analyst estimates.

The low price target for JNJ is $133.00, while the high price target is $182.00.

JNJ analyst rating is Buy.


6. JNJ buy or sell? What is JNJ Finny Score?

Our quantitative analysis shows 5 reasons to buy and 2 reasons to sell JNJ, resulting in Finny Score of 71.

7. What are the reasons to buy JNJ? Why should I buy JNJ stock?

Here are the reasons to buy JNJ stock:

  • The majority of J&J's near-term patent losses are for products that are hard to make, including the biologic drug Remicade, which should slow generic competition.
  • Diverse healthcare segments insulate J&J from downturns in the economy, offering a defensive growth opportunity with a stable and likely growing dividend.
  • Several of Johnson & Johnson's key drugs and pipeline drugs are specialty drugs that tend to carry stronger pricing power and lower regulatory hurdles for approval.
  • Johnson & Johnson struck several deals, which should boost its top line. The Cougar Biotechnology acquisition allowed Johnson & Johnson to strengthen its oncology portfolio especially in the areas of advanced prostate cancer, breast cancer and multiple myeloma. The acquisition has proved its worth with the approval of prostate cancer therapy, Zytiga.
  • Johnson & Johnson continues to work on strengthening its Pharma segment, which has been driving revenues over the past few quarters. Johnson & Johnson expects to launch or file for approval for more than 10 new blockbuster products by 2021. The company said that each of these products has blockbuster potential.
  • Apart from established products in the pharma segment, new products like Imbruvica, Xarelto and Darzalex are performing well. Zytiga and Imbruvica are notably successful launches in the company’s oncology portfolio. The company is also working on expanding the label of currently marketed products like Simponi, Stelara, Zytiga and Imbruvica.
  • Johnson & Johnson is looking to increase its presence in emerging markets as they hold immense potential. Given the huge potential, the company has set up manufacturing and R&D centers in Brazil, China and India, and has almost doubled its footprint in emerging markets in the last five years. These countries are trying to make healthcare accessible to more people primarily by improving insurance coverage. Johnson & Johnson intends to continue working on strengthening its pipeline in Japan as well as China.
  • JNJ quarterly revenue growth was 3.30%, higher than the industry and sector average revenue growth (1.95% and 1.16%, respectively). See JNJ revenue growth chart.
  • JNJ forward dividend yield is 2.75%, higher than the industry (0.76%) and sector (0.16%) forward dividend yields. See JNJ forward dividend chart.
  • JNJ average analyst rating is Buy. See JNJ analyst rating chart.
  • JNJ average analyst price target ($164.17) is above its current price ($141.04). See JNJ price target chart.
  • JNJ cash to debt ratio is 0.65, higher than the average industry (0.15) and sector (0.16) cash to debt ratio. See JNJ cash to debt chart.

8. What are the reasons to sell JNJ? Why should I sell JNJ stock?

Let's look at the reasons to sell JNJ stock (i.e., the bear case):

  • Product recalls and manufacturing issues in the consumer business could dent Johnson & Johnson's powerful brand name in a segment where brand recognition is critical.
  • Potential legal action regarding product recalls for hip and knee replacements along with several consumer products could damage the company's image, cost billions of dollars, and create distractions for management.
  • Several of Johnson & Johnson's important drugs are facing increasing competition, which should slow the growth rate of the pharmaceutical group.
  • Quite a few products in the company’s portfolio including Invega and Ortho Tri-Cyclen Lo are facing generic competition. Moreover, biosimilar competition for Remicade entered several major EU markets in February 2015.
  • The labels of products like Remicade and Simponi contain warnings regarding the risk of cancer in children and teenagers. The inclusion of such warnings could lead to restricted sales of these products. In Feb 2010, the FDA approved a risk management program (RiskMap) to inform about the risks of erythropoiesis-stimulating agents (ESAs).
  • Johnson & Johnson has suffered its share of pipeline setbacks. These include failure to gain approval for ceftobiprole (the company returned global rights for the candidate to its Swiss partner, Basilea Pharmaceuticals), a third CRL for the supplemental new drug application (sNDA) for Xarelto for acute coronary syndrome (ACS) and the withdrawal of the EU application for an additional indication for Velcade for the treatment of patients with relapsed follicular non-Hodgkin lymphoma. Johnson & Johnson also announced that it no longer intends to seek EU approval for Risperdal Consta for bipolar I disorder.
  • JNJ profitability is declining. The YoY profit margin change was -21.31 percentage points. See JNJ profitability chart.
  • JNJ Price/Sales ratio is 4.70, which is high compared to its industry peers’ P/S ratios. See JNJ forward Price/Sales ratio chart.

Key Stats

9. What are JNJ key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for JNJ:

Metrics JNJ
Price $142.47
Average Price Target / Upside $164.17 / 15.23%
Average Analyst Rating Hold
Forward Dividend Yield 2.75%
Industry Drug Manufacturers - Major
Sector Healthcare
Number of Employees 135,100
Market Cap $389.23B
Forward P/E Ratio 16.30
Price/Book Ratio 4.7
Revenue (TTM) $82.73B
YoY Quarterly Revenue Growth 3.30%
Profit Margin 20.75%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us